Fusidic Acid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Fusidic Acid: From Staphylococcal Infections to Exposure Keratitis
One-Sentence Summary
Fusidic acid is an established antibacterial agent, best known for its potent activity against Staphylococcus aureus (including MRSA) in skin and soft-tissue infections. The TxGNN model predicts it may have a role in exposure keratitis, specifically as prophylaxis/treatment for secondary bacterial infection of the exposed corneal surface, but currently only 0 clinical trials and 1 case-series publication support this specific direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Antibacterial use (staphylococcal infections, e.g. skin and skin structure infections) — a specific original indication text is not documented in this evidence pack |
| Predicted New Indication | Exposure keratitis |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold (TxGNN stage: “Research Question”, S1) |
Why is This Prediction Reasonable?
Detailed original mechanism-of-action data is flagged as a gap in this evidence pack (data gap DG002, High severity). Based on information available elsewhere in the pack, fusidic acid is a protein synthesis inhibitor that blocks EF-G-mediated ribosomal translocation, giving it potent bactericidal/bacteriostatic activity against Staphylococcus aureus, including MRSA. This antibacterial profile is well established for staphylococcal skin, soft-tissue and ocular infections.
Exposure keratitis is a structural/mechanical corneal injury — typically from inadequate eyelid closure — rather than a primary infection. However, a chronically exposed corneal surface is prone to secondary bacterial infection, including from opportunistic organisms. TxGNN’s prediction therefore does not imply fusidic acid treats the underlying exposure pathology itself, but rather positions it as a candidate topical antimicrobial for preventing or treating secondary infection in this setting.
This mechanistic link is plausible because fusidic acid eye preparations are already used clinically for ocular staphylococcal infections, so extending this activity to infection-prophylaxis in exposure keratitis is a reasonable pharmacological extrapolation. That said, this is currently a mechanism-based hypothesis rather than a therapeutically validated use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31246677 | 2019 | Case series | Cornea | Largest reported case series of ophthalmic Tsukamurella infections (an emerging opportunistic pathogen), including the first report of ocular implant infection after enucleation — relevant to secondary infection risk on a compromised/exposed corneal surface, but does not directly evaluate fusidic acid treatment. |
Australia Market Information
Fusidic acid currently has no ARTG entries and is not marketed in Australia (total licenses: 0).
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. Note: TFDA/PI-equivalent warnings and contraindications data is flagged as a Blocking data gap (DG001) in this evidence pack, meaning a formal safety assessment (S1) cannot currently proceed without this information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for exposure keratitis is limited to a single tier-3 case series with no supporting clinical trials, and TxGNN itself stages this candidate at the earliest evidence tier (“Research Question”, S1). This is insufficient to justify progression at this time.
To proceed, the following is needed:
- TGA/PI-equivalent warnings and contraindications (currently a Blocking data gap)
- Confirmed original mechanism-of-action documentation (currently a High-severity data gap)
- Preclinical or clinical evidence directly evaluating topical fusidic acid for secondary infection prevention/treatment in exposure keratitis
- ARTG registration pathway assessment, since the drug is not currently marketed in Australia
Note: This evidence pack contains other fusidic acid candidates with substantially stronger evidence — notably rank 5, “post-bacterial disorder” (Evidence Level L1, decision stage S2, “Proceed with Guardrails”), supported by a completed Phase 3 RCT (NCT02570490, oral sodium fusidate vs. linezolid in ABSSSI, n=716). A separate report on that candidate may be of more immediate practical interest.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.